mRNA Synthesis Raw Materials Market Size, Share & Trends Analysis Report By Type (Capping Agents, Nucleotides, Plasmid DNA, Enzymes), By Application (Vaccine Production, Therapeutics Production), By End-use, By Region, And Segment Forecasts, 2025 - 2030

mRNA Synthesis Raw Materials Market Summary

Growth of mRNA Vaccines and Therapeutics

The rapid development and global deployment of mRNA vaccines, especially during the COVID-19 pandemic, has revolutionized the field of vaccinology and therapeutic development. Companies like Pfizer-BioNTech and Moderna demonstrated that mRNA technology can be rapidly developed and mass-produced to combat infectious diseases effectively. This large-scale production requires significant quantities of high-quality nucleotides, enzymes, and specialized modified nucleosides that enhance mRNA stability and reduce immune reactions. As global vaccination campaigns continue and expand, the need for these critical raw materials remains high to support ongoing manufacturing efforts.

The potential of mRNA therapeutics in treating cancer, rare genetic disorders, and other diseases is fueling further market growth. The expanding pipeline of mRNA-based drugs requires consistent supplies of GMP-grade raw materials that meet stringent regulatory standards. For instance, in April 2024, CureVac and MD Anderson Cancer Center initiated a strategic collaboration to develop off-the-shelf mRNA-based cancer vaccines for hematological and solid tumors. This partnership leverages CureVac’s end-to-end mRNA capabilities and MD Anderson’s clinical research expertise. Moreover, innovations in mRNA synthesis technologies drive demand for more advanced and specialized reagents. These factors make developing and producing mRNA vaccines and therapeutics a dominant driver of the growing mRNA synthesis raw materials market.

Technological Improvements in mRNA Synthesis Technology

Advancements in mRNA synthesis technologies have significantly boosted the demand for specialized raw materials. Modern mRNA production now incorporates chemically modified nucleotides, such as pseudouridine and 5-methylcytidine, which help improve mRNA stability, increase protein translation efficiency, and reduce unwanted immune activation. For instance, in March 2025, Telesis Bio secured up to USD 21 million in funding to accelerate the adoption of its Gibson SOLA technology for rapid DNA and mRNA synthesis. This advanced technology enables researchers to produce high-quality nucleic acids on-site, reducing reliance on external suppliers and enhancing control over the synthesis process. Moreover, innovations in enzymatic synthesis methods and optimized in vitro transcription protocols demand high-performance enzymes and reagents designed for improved yield and purity, further intensifying the need for advanced raw materials.

Technological progress extends beyond synthesis to include improved delivery systems, such as lipid nanoparticles (LNPs), which protect mRNA and facilitate cellular uptake. The production of these delivery vehicles also depends on specialty lipids and excipients that must meet rigorous quality and regulatory requirements. These technological improvements create a ripple effect, driving the demand for sophisticated raw materials across the entire mRNA manufacturing supply chain. As researchers continue to refine and innovate mRNA therapies and vaccines, the market for these raw materials is expected to grow steadily, reflecting the complexity and precision of next-generation mRNA raw material products.

Market Concentration & Characteristics

The degree of innovation in the mRNA synthesis raw materials industry is significant, with new technologies and processes constantly being developed to improve efficiency and effectiveness. The mRNA field is expected to evolve rapidly, with ongoing research leading to discoveries and applications. For instance, in April 2024, Moderna and OpenAI announced a strategic collaboration to advance mRNA medicine by integrating generative AI tools across Moderna's operations. This partnership aims to accelerate the development of mRNA-based therapeutics by leveraging AI to enhance productivity and innovation. Innovations in raw materials can improve mRNA therapeutics' stability, delivery, and efficacy, broadening their therapeutic applications and improving patient outcomes.

Mergers and acquisition activities can significantly impact the growth of the mRNA synthesis raw materials industry. Partnerships help companies to reduce costs and increase efficiency. In February 2022, Merck KGaA acquired Exelead for around USD 780 million in cash to reinforce its life sciences business segment. The initiative expanded the company’s life sciences portfolio and improved its market presence.

The regulatory landscape for mRNA-based products is stringent, with a strong focus on ensuring safety, efficacy, and quality control. For instance, BioNTech received FDA approval for a novel mRNA cancer vaccine that utilized a newly developed modified nucleotide raw material, which met rigorous regulatory criteria and demonstrated improved patient tolerance, underscoring the importance of regulatory-compliant raw materials in advancing mRNA therapeutics. Innovative raw materials that meet high regulatory standards streamline the approval process and reduce the risk of adverse effects and manufacturing inconsistencies, thereby accelerating the availability of new mRNA therapies to patients. Compliance with GMP (Good Manufacturing Practices) guidelines and FDA or EMA requirements is critical for market entry and patient safety

The mRNA synthesis raw materials industry is experiencing growth due to the expanding applications of mRNA technology, advancements in biotechnology & production processes, and increased research and development investments. mRNA technology allows for the development of personalized treatments tailored to individual genetic profiles. For instance, in May 2025, a groundbreaking mRNA-based personalized CRISPR therapy was successfully administered to a baby with a rare genetic disorder, marking the first instance of such treatment tailored to an individual's DNA. This achievement underscores the increasing demand for mRNA synthesis raw materials as personalized medicine advances. Thus, the personalized approach requires specific raw materials that can be customized for definite applications, boosting demand in the market.

The mRNA synthesis raw materials industry has witnessed significant regional expansion in recent years. Companies are expanding their manufacturing capacities to meet the growing global demand for mRNA products. This includes establishing new production facilities and scaling up existing ones in various regions. For instance, in September 2022, TriLink BioTechnologies, a Maravai LifeSciences company, expanded its GMP-grade mRNA raw material offerings by introducing N1-Methyl-Pseudouridine-5’-Triphosphate (N1meΨTP), a critical modified nucleoside-triphosphate essential for mRNA manufacturing. This addition enables researchers to accelerate drug discovery and development timelines while sourcing materials domestically. The move underscores the increasing demand for high-quality mRNA synthesis raw materials, including nucleotides and specialized enzymes, as the industry scales up mRNA-based therapeutics and vaccines.

Type Insights

The nucleotides segment dominated the global industry in 2024, accounting for 37.06% of total revenue. The increasing demand for high-purity nucleotides essential for efficient and accurate mRNA synthesis in vaccine development, therapeutics, and research applications primarily drives this growth. The segment's leadership reflects its critical role in ensuring the stability and fidelity of synthesized mRNA sequences. Moreover, advancements in nucleotide modification technologies and the expansion of biopharmaceutical pipelines have further fueled the segment's rapid growth and widespread adoption in the mRNA synthesis raw material market.

The capping agents segment is expected to grow with the fastest CAGR of 6.42% over the forecast period. Capping and tailing are essential steps in producing active mRNA for functional studies. Key players in the market are developing capping technology for industries to support the development of mRNA therapeutics and vaccines. For instance, in May 2025, TriLink BioTechnologies, a Maravai LifeSciences company, launched its first mRNA synthesis kit featuring CleanCap capping technology to streamline in vitro transcription with higher yield and lower dsRNA content. The kit includes optimized components such as CleanCap AG (3′ OMe) and CleanScribe RNA Polymerase, supporting efficient and high-quality mRNA production. This launch reflects the growing demand for premium mRNA synthesis raw materials as the global development of mRNA-based therapeutics and vaccines continues to expand. As a result, the continuous advancements of capping technology are anticipated to boost segment growth and fuel the market for mRNA synthesis raw material.

Application Insights

The vaccine production segment held the largest revenue market share at 83.93% in 2024. This can be attributed to the rapid production of mRNA vaccines compared to the conventional vaccines that utilize cell-culture-based production paths, which are often prone to failure. Moreover, advancements in mRNA and the need to ramp up production capacity to meet global demand are providing opportunities to build flexible vaccine manufacturing facilities globally. For instance, in April 2024, IDT Australia and Sanofi entered into a Master Service Agreement for the cGMP manufacture of SaSanofi's RNA vaccines at IDIDT's Melbourne facility. This collaboration aims to advance mRNA-based vaccine formulation and development for clinical trials targeting various medical conditions. Hence, increasing demand for vaccines drives the need for raw materials, boosting market growth.

The therapeutics production segment is expected to expand at a significant CAGR during the forecast period due to the increasing prevalence of various chronic and infectious diseases. For instance, according to data published by the World Health Organisation (WHO), 1.25 million people died from tuberculosis (TB) in 2023. mRNA-based therapeutics present promising treatment strategies for several diseases but also help in prevention. Hence, there is an increase in clinical trials and in vivo models to produce various therapeutics based on mRNA platforms, which will likely aid revenue generation in this segment. For instance, in September 2024, Primrose Bio and ExPLoRNA Therapeutics announced a strategic partnership to advance mRNA medicines. They aim to co-develop RNA polymerases and capping compounds to enhance mRNA quality, manufacturing efficiency, and therapeutic efficacy, addressing the growing demand for mRNA synthesis raw materials.

End-use Insights

The biopharmaceutical and pharmaceutical companies segment dominated the market. It accounted for the highest revenue share of 49.33% in 2024 due to the high commercial success of biopharmaceuticals and rapid growth in demand for therapeutics. Significant growth in the pharmaceutical industry pipeline has boosted the need for raw materials synthesized from mRNA to discover novel therapeutics. For instance, in June 2025, BioNTech and Bristol Myers Squibb announced a strategic partnership to co-develop and commercialize BNT327, a bispecific antibody targeting PD-L1 and VEGF-A for cancer treatment. BNT327 is currently in multiple Phase 3 trials for various cancers, including lung and breast cancer. This collaboration underscores the increasing demand for raw materials for mRNA synthesis to support the development and manufacturing of mRNA-based therapeutics and vaccines.

The Contract Research Organizations (CROs) segment is anticipated to grow at a significant CAGR throughout the forecast period. This rapid expansion is attributed to the increasing outsourcing of mRNA research, development, and clinical trial activities by biopharmaceutical companies seeking to reduce costs and accelerate timelines. CROs offer specialized expertise, advanced technologies, and regulatory support, making them ideal partners in mRNA-based drug and vaccine development. The rising demand for customized mRNA synthesis services and scalable manufacturing solutions is further driving the growth of this segment.

Regional Insights

North America mRNA synthesis raw material industry dominated in 2024 and accounted for the largest share of 36.13% of the overall revenue. The presence of local players, such as Providence Therapeutics, which offers personalized mRNA vaccines to treat chronic diseases, including cancer, is expected to aid revenue generation in the region. Several innovations by local players in the region are also expected to drive the mRNA synthesis raw materials market to a certain extent.

U.SmRNA Synthesis Raw Material Market Trends

The mRNA synthesis raw materials industry in the U.S. is expected to grow over the forecast period. The rising research funding, presence of key players, and availability of healthcare infrastructure are expected to contribute to the high revenue share. For instance, in August 2023, Applied DNA Sciences announced the availability of its Linea IVT Evaluation Kit, marking a significant advancement in mRNA synthesis technology. This kit combines Linea IVT templates, a proprietary buffer system, and Linea RNA polymerase (RNAP) to streamline in vitro transcription (IVT) processes, further driving the market expansion.

Europe mRNA Synthesis Raw Material Market Trends

Europe mRNA synthesis raw materials industry was identified as a lucrative region in this industry. The strong presence of well-established and emerging product manufacturers and the continuous organic and inorganic growth strategies they adopt are expected to create a lucrative environment for market growth. Offerings can be adapted for research use only (RUO) or manufactured at GMP grade, supporting the advancement of mRNA-based therapeutic innovations.

The mRNA synthesis raw materials market in the UK held a significant share in 2024. Growing government deals with companies active in the mRNA space are being signed within the country to manage the pandemic. For instance, in July 2024, UK-based CDMO Touchlight signed a non-exclusive license agreement with GSK to use its proprietary enzymatic doggybone DNA (dbDNA) technology for mRNA vaccine manufacturing. This enables GSK to rapidly and scalably produce GMP-grade DNA templates essential for mRNA-based therapeutics, particularly for seasonal and pandemic vaccines, further driving the demand in the mRNA synthesis raw material industry.

Germany mRNA synthesis raw materials market is anticipated to grow significantly over the forecast period. For instance, in February 2023, BioNTech announced an investment in a new facility in Marburg, Germany, to produce plasmid DNA, a crucial building block for mRNA-based drugs. This facility comprises two clinical and commercial scale manufacturing plants, enhancing BioNTech's control over its supply chain. Thus, increasing investments in mRNA technology are anticipated to drive the market in the region during the forecast period

Asia Pacific mRNA Synthesis Raw Material Market Trends

The mRNA synthesis raw materials market in Asia Pacific held a significant CAGR of 6.22% over the forecast period. With rising healthcare spending and investments in the region, many raw material manufacturers are shifting operations to Asia Pacific countries, which is contributing to the growing demand for the market. For instance, in November 2024, Singapore inaugurated the NATi mRNA BioFoundry, Asia's first automated facility dedicated to mRNA manufacturing. The non-GMP BioFoundry is designed to advance nucleic acid therapeutics through automation, machine learning, and integration with the Wellcome Leap R3 Program. Moreover, the region's large population base and increasing government support for biotechnology innovation further fuel market expansion.

China mRNA synthesis raw materials market is expected to grow over the forecast period. The growing popularity of mRNA drugs and vaccines has created opportunities for raw material manufacturers to innovate and collaborate with these companies. For instance, in February 2022, Walvax Biotechnology, in collaboration with Honeywell, inaugurated China's first digital mRNA vaccine production facility in Yunnan Province. The facility is designed to support the rapid and scalable manufacturing of mRNA vaccines, addressing domestic and international health needs. Moreover, companies such as Blue Que Bio, Ceno Bio, Aibo Bio, Zhongmei Ruikang, Ruibo Bio, Sri Microbe, Shenxin Bio, Ribo Bio, Zhiyuan Messenger, Gemma Gene, and others are developing the technology of mRNA drugs or pipeline layout.

The mRNA synthesis raw materials market in Japan is witnessing significant growth over the forecast period. Major players in the market are adopting several strategies, including mergers and acquisitions, partnerships, and collaborations, to stay competitive. For instance, in July 2024, Moderna and Mitsubishi Tanabe Pharma Corporation entered into a joint agreement to co-promote Moderna’s mRNA respiratory vaccine portfolio in Japan, further expanding the mRNA synthesis raw materials industry in the region.

Middle East and Africa mRNA Synthesis Raw Material Market Trends

The MEA mRNA synthesis raw materials market is expected to grow exponentially over the forecast period. MEA region is witnessing significant growth due to improved infrastructure and policies laid down by regulatory bodies. The rising disposable income and increasing geriatric population are major factors driving market growth. Furthermore, many multinational companies, such as F. Hoffmann-La Roche Ltd, plan to focus on the MEA market by forming joint ventures with local companies, such as Whitehead Scientific, for the raw materials required for regional mRNA synthesis. For instance, in February 2025, TriLink Biotechnologies and Avantor announced a distribution partnership to expand the availability of TriLink's nucleic acid products across Europe, the Middle East, and Africa (EMEA). These strategic collaborations and investments are expected to strengthen the supply chain and improve access to high-quality raw materials, accelerating the region's development and production of mRNA-based therapies.

Kuwait's mRNA synthesis raw materials market is anticipated to experience growth over the forecast period. Several multinational and regional pharmaceutical companies are expected to be active in the Kuwaiti market, particularly offering mRNA vaccines during winter when the risk of seasonal flu increases. This seasonal demand will likely drive higher consumption of raw materials required for mRNA synthesis, thereby boosting the country's overall market growth. Moreover, increasing government initiatives to improve healthcare infrastructure and vaccine awareness campaigns are expected to support expanding Kuwait's mRNA raw materials market further.

Key mRNA Synthesis Raw Material Company Insights

Key players operating in the mRNA synthesis raw material indudtry are undertaking various initiatives to strengthen their presence and increase the reach of their products and services. Strategies such as expansion activities and partnerships are key in propelling the market growth.

Recent Developments

• In November 2024, Syvento Biotech and Cytiva inaugurated a FlexFactory facility in Poland to accelerate mRNA therapy development. The modular platform integrates automation and digital tools, enhancing production efficiency and scalability. This collaboration bolsters regional manufacturing capabilities and expedites patient access to innovative treatments.

• In September 2024, Hongene Biotech Corporation and ReciBioPharm announced a strategic partnership to enhance gene editing drug manufacturing. This collaboration integrates Hongene's proprietary sgRNA synthesis technology into ReciBioPharm's facilities in Watertown, Massachusetts, enabling comprehensive services, including plasmid, mRNA, sgRNA, LNP, and fill-finish capabilities under one roof. The alliance aims to streamline the development and manufacturing process, reducing logistical complexities and accelerating drug development timelines.

• In February 2022, Merck KGaA, Darmstadt, Germany, completed its acquisition of Exelead, a U.S.-based CDMO. The deal aimed to enhance Merck's mRNA vaccine and therapeutic development capabilities. Merck committed to investing in scaling up Exelead's technology over the next ten years.

mRNA Synthesis Raw Material Market Report Scope

Global mRNA Synthesis Raw Materials Market Report Segmentation

This report forecasts revenue growth at the global, regional, and country levels and provides an analysis on the latest trends in each of the sub-segments from 2018 to 2030. For this study, Grand View Research has segmented the global mRNA synthesis raw material market report on the basis of type, application, end-use, and region:

• Type Outlook (Revenue, USD Million, 2018 - 2030)

  • Capping Agents

    • CleanCap Reagents

    • ARCA (Anti-Reverse Cap Analog)

    • Others

  • Nucleotides

    • Modified Nucleic Acids

      • N1-methylpseudouridine-triphosphate

      • 5-Methylcytidine triphosphate (5mCTP)

    • Natural Nucleic Acids

      • Adenine

      • Guanine

      • Cytosine

      • Uracil

  • Plasmid DNA

  • Enzymes

    • Polymerase

    • RNase Inhibitor

    • DNase

    • Others

  • Others

• Application Outlook (Revenue, USD Million, 2018 - 2030)

  • Vaccine Production

  • Therapeutics Production

  • Others

• End-use Outlook (Revenue, USD Million, 2018 - 2030)

  • Biopharmaceutical & Pharmaceutical Companies

  • CROs & CMOs

  • Academic & Research Institutes

• Regional Outlook (Revenue, USD Million, 2018 - 2030)

  • North America

    • U.S.

    • Canada

    • Mexico

  • Europe

    • UK

    • Germany

    • France

    • Italy

    • Spain

    • Denmark

    • Sweden

    • Norway

  • Asia Pacific

    • Japan

    • China

    • India

    • South Korea

    • Australia

    • Thailand

  • Latin America

    • Brazil

    • Argentina

  • Middle East & Africa

    • South Africa

    • Saudi Arabia

    • UAE

    • Kuwait